NRIX Earnings Date: Feb 17, 2027 (Estimated) — Nurix Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is NRIX's next earnings date?
Nurix Therapeutics, Inc. (NRIX) is expected to report Q4 2026 earnings on Wednesday, February 17, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.39 on revenue of $218.4M.
How did NRIX do in its last earnings report?
In its most recent report on Oct 12, 2026 (Q3 2026), Nurix Therapeutics, Inc. posted EPS of $4.73 versus the -$0.60 estimate, a beat of 887.1%. Revenue was $673.1M against a $24.3M estimate. The stock's 1-day post-earnings move was -0.1%.
How much does NRIX stock move after earnings?
NRIX beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.2% (up or down) in the day after earnings.
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
🤖 AI Earnings Analysis
Nurix’s key catalyst is dosing the first patient in the registrational Phase 3 DAYBreak CLL-306 trial, validating bexobrutideg’s path in relapsed/refractory CLL/SLL. Revenue surged to **$673M** from $8M, but the beat looks milestone-driven and losses remain heavy at **-$91M** operating income.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-12 | Q3 2026 | -0.60 | 4.73 | +887.15% | $673.1M | ✅ Beat | -0.14% | +12.50% | — |
| 2026-07-09 | Q2 2026 | -0.72 | -0.81 | -12.50% | $9.0M | ❌ Miss | -6.60% | -6.56% | +3.40% |
| 2026-04-08 | Q1 2026 | -0.76 | -0.79 | -3.95% | $6.3M | ❌ Miss | -4.59% | -0.31% | +3.24% |
| 2026-01-28 | Q4 2025 | -0.89 | -0.82 | +7.87% | $13.6M | ✅ Beat | -1.57% | -7.39% | -10.63% |
| 2025-10-09 | Q3 2025 | -0.85 | -1.03 | -21.18% | $7.9M | ❌ Miss | -10.13% | -7.64% | +13.35% |
| 2025-04-08 | Q1 2025 | -0.78 | -0.67 | +14.10% | $18.5M | ✅ Beat | +3.67% | +6.05% | +4.10% |
| 2025-01-28 | Q4 2024 | -0.71 | -0.75 | -5.63% | $13.3M | ❌ Miss | +0.46% | -4.96% | -23.31% |
| 2024-10-11 | Q3 2024 | -0.72 | -0.67 | +6.94% | $12.6M | ✅ Beat | +6.47% | +6.01% | +19.09% |
Showing last 8 quarters.